Lonza and Agilent Announce Cell Therapy Collaboration
Contract development and manufacturing organization Lonza (Basel, Switzerland) and Agilent Technologies (Santa Clara, California, USA) have agreed a collaboration deal to transform the manufacturing process for personalized cell therapies
Cell therapies are a rapidly growing and developing industry with a number of products in clinical development. Inherently complex with highly specific patient needs, cell therapies represent an uncompromising challenge to researchers because ensuring product consistency requires real-time information on critical quality attributes (CQAs) and analytics throughout the production process. Minor changes during manufacturing could potentially cause major changes in the quality and efficacy of the final product.
The deal will see Agilent integrate its analytics technologies with Lonza’s Cocoon cell manufacturing platform. The companies hope that by integrating Agilent analytical technologies both at-line and in-line within the Cocoon platform automated manufacturing workflows manufacturers will be able to ensure that in-process controls and analytics can be employed on-demand to deliver a more consistent drug product.
“There is a huge opportunity through this partnership to determine what the ideal critical quality attributes are for manufacturing the most effective cell therapy, and drive the manufacturing, optimally in real-time, to meet those criteria,” said Nicholas Ostrout, Senior Director, Business Strategy and Implementation, Personalized Medicine, at Lonza.
For more information, please visit: www.lonza.com or www.agilent.com
Measuring Procyanidin Concentration in Wines Using UHPLC
January 24th 2025Researchers from the University of Bordeaux (Villenave d'Ornon, France) report the development and validation of a rapid and quantitative analytical method measuring crown procyanidin concentration in red and white wines using ultra-high performance liquid chromatography (UHPLC) coupled with a ultra-high performance liquid chromatography (Q-TOF) mass spectrometer.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Testing Solutions for Metals and PFAS in Water
January 22nd 2025When it comes to water analysis, it can be challenging for labs to keep up with ever-changing testing regulations while also executing time-efficient, accurate, and risk-mitigating workflows. To ensure the safety of our water, there are a host of national and international regulators such as the US Environmental Protection Agency (EPA), World Health Organization (WHO), and the European Union (EU) that demand stringent testing methods for drinking water and wastewater. Those methods often call for fast implementation and lengthy processes, as well as high sensitivity and reliable instrumentation. This paper explains how your ICP-MS, ICP-OES, and LC-MS-MS workflows can be optimized for compliance with the latest requirements for water testing set by regulations like US EPA methods 200.8, 6010, 6020, and 537.1, along with ISO 17294-2. It will discuss the challenges faced by regulatory labs to meet requirements and present field-proven tips and tricks for simplified implementation and maximized uptime.
